You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
GW 1929 hydrochloride
Biological Activity for GW 1929 hydrochloride
GW 1929 hydrochloride is a highly selective orally active peroxisome proliferator-activated receptor (PPAR)γ agonist (pEC50 values are 8.05, < 4 and < 4 for human PPARγ, PPARα and PPARδ receptors respectively). Decreases glucose, fatty acid and triglyceride levels following oral administration in vivo.
Sold for research purposes under agreement from GlaxoSmithKline
Technical Data for GW 1929 hydrochloride
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for GW 1929 hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||49.56||100 with gentle warming|
Preparing Stock Solutions for GW 1929 hydrochloride
The following data is based on the product molecular weight 532.03. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.88 mL||9.4 mL||18.8 mL|
|5 mM||0.38 mL||1.88 mL||3.76 mL|
|10 mM||0.19 mL||0.94 mL||1.88 mL|
|50 mM||0.04 mL||0.19 mL||0.38 mL|
Product Datasheets for GW 1929 hydrochloride
References for GW 1929 hydrochloride
References are publications that support the biological activity of the product.
Brown et al (1999) A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48 1415 PMID: 10389847
Nugent et al (2001) Potentiation of glucose uptake in 3T3-L1 adipocytes by PPARγ agonists is maintained in cells expressing a PPARγ dominant-negative mutant: evidence for selectivity in the downstream responses to PPARγ activation. Mol.Endocrinol. 15 1729 PMID: 11579205
Way et al (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists. J.Biol.Chem. 276 25651 PMID: 11373275
If you know of a relevant reference for GW 1929 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: GW 1929 hydrochloride, GW 1929 hydrochloride supplier, Selective, PPARγ, PPARgamma, agonists, orally, active, Peroxisome, Proliferator-activating, Receptors, PPAR, GW1929, hydrochloride, GlaxoSmithKline, GSK, 1664, Tocris Bioscience
2 Citations for GW 1929 hydrochloride
Citations are publications that use Tocris products. Selected citations for GW 1929 hydrochloride include:
Chai et al (2013) Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells. PLoS One 8 e62934 PMID: 23658787
Hatano et al (2010) Murine atopic dermatitis responds to peroxisome proliferator-activated receptors α and β/δ (but not γ) and liver X receptor activators. Endocrinology 125 160 PMID: 19818482
Do you know of a great paper that uses GW 1929 hydrochloride from Tocris? Please let us know.
Reviews for GW 1929 hydrochloride
There are currently no reviews for this product. Be the first to review GW 1929 hydrochloride and earn rewards!
Have you used GW 1929 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.